Karuna’s schiz­o­phre­nia drug clears an­oth­er PhI­II as biotech seeks 2024 launch

Karuna Ther­a­peu­tics said its in­ves­ti­ga­tion­al schiz­o­phre­nia treat­ment cleared the bar in an­oth­er Phase III clin­i­cal tri­al, which the biotech hopes will open the doors for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER